anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1514469 Oral hygiene compositions BEECHAM GROUP Ltd 18 July 1975 [1 Aug 1974] 33951/74 Heading A5B Compositions for oral hygiene e.g. mouthwashes, toothpastes, chewing gum, comprise by weight of the composition, 0.1-5% of an antibacterial component comprising one or more pharmaceutically acceptable esters of ohydroxybenzoic acid and/or of p-hydroxybenzoic acid, 0.1-5% of a vitamin or vitamin-like component comprising one or more of aescin, rutin, panthenol, nicotinamide and vitamin E, and 0.1-5% of a surfactant, the weight ratio of antibacterial component to surfactant being from 1:5 to 5:1. Other antibacterial agents e.g. o-phenylphenol or phenoxyethanol, and other vitamins e.g. vitamins C, K and B group may be present. The surfactant is preferably anionic e.g. fatty alkyl sulphates, fatty alkyl ether sulphates, or may be cationic. The compositions may also contain anticariogenic fluorides. The preferred vehicle is an aqueous alcohol.
PURPOSE: A cosmetic composition containing Panax ginseng C.A. Meyer powder is provided to ensure scrub effect and to promote blood circulation on the face. CONSTITUTION: A cosmetic composition contains Panax ginseng C.A. Meyer powder. The size of Panax ginseng C.A. Meyer powder is 150um to 450 um. The cosmetic composition is used in the form of toner, emulsion, essence, cleansing cream, BB cream, foundation, or pack.
PURPOSE: To obtain a non-sensitizing biocide composition reduced in the sensitizing ability of a 3-isothiazolone biocide and used for controlling fungi and preventing fouling by encapsulating the 3-isothiazolone in polyurea particles and subsequently dispersing the particles in a composition. CONSTITUTION: This non-sensitizing biocide composition is obtained by encapsulating a 3-isothiazolone biocide in polyurea particles and subsequently dispersing the particles in a composition. The 3-isothiazolone is preferably 4,5-dichloro-2-n- octyl-3-isothiazolone or 2-n-octyl-3-isothiazolone. The polyurea is obtained by polymerizing one or more polyisocyanates with one or more polyamines in the presence of the 3-isothiazolone. The polyamine is preferably selected from the group consisting of diethyleneamine, triethyleneamine and tetraethyleneamine. The polyisocyanate is preferably polymethylenepolyphenylisocyanate, 2,6- toluenediisocyanate, etc. The diameters of the particles are preferably <40 μm.
The invention provides traditional Chinese medicine for treating young animals suffering from viral diarrhea. The traditional Chinese medicine comprises, by weight, 5-33 parts of cyrtomium rhizome, 2-30 parts of schisandra chinensis, 3-20 parts of pomegranate rind, 38.5-85.13 parts of flavoring agents and 4.87-34.2 parts of disintegrants. The flavoring agents comprise 4-80 parts of mannitol, 5-30 parts of cane sugar, 0.05-3 parts of potassium chloride, 0.05-0.5 part of sodium glutamate, 0.02-0.5 part of trisodium glycyrrhizinate and 0.01-0.5 part of fresh milk essence; the disintegrants comprise 3.5-26 parts of microcrystalline celluloses, 1.25-5 parts of low-substituted hydroxypropyl celluloses, 0.1-2.5 parts of magnesium stearate and 0.02-1 part of sodium dodecyl sulfate. The invention further discloses a method for manufacturing the traditional Chinese medicine. The method includes decocting the cyrtomium rhizome and the schisandra chinensis in water to obtain filter liquid, adding powder of the pomegranate rind into the filter liquid to obtain soft materials, adding the magnesium stearate into the soft materials, uniformly mixing the magnesium stearate and soft materials with one another to obtain mixtures, granulating the mixtures to obtain grains and drying the grains; adding the mannitol, the microcrystalline celluloses, the low-substituted hydroxypropyl celluloses, the sodium dodecyl sulfate, the magnesium stearate, the trisodium glycyrrhizinate and the fresh milk essence into the grains and uniformly mixing the mannitol, the microcrystalline celluloses, the low-substituted hydroxypropyl celluloses, the sodium dodecyl sulfate, the magnesium stearate, the trisodium glycyrrhizinate and the fresh milk essence with the grains. The invention further discloses application of the traditional Chinese medicine to treating the young animals suffering from viral diarrhea. The traditional Chinese medicine, the method and the application have the advantages of zero irritability and excellent curative effect.
10.1 Human Experience

In clinical trials of escitalopram, there were reports of escitalopram overdose, including overdoses of up to 600 mg, with no associated fatalities. During the postmarketing evaluation of escitalopram, escitalopram oxalate overdoses involving overdoses of over 1000 mg have been reported. As with other SSRIs, a fatal outcome in a patient who has taken an overdose of escitalopram has been rarely reported. 

Symptoms most often accompanying escitalopram overdose, alone or in combination with other drugs and/or alcohol, included convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose.

10.2 Management of Overdose

Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of escitalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for escitalopram oxalate.

In managing overdosage, consider the possibility of multiple-drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose.
The assumption is that researchers can engineer synthetic metabolic and genetic networks to expand the panel of molecules that are currently known to be detected by natural systems. The investigators also hypothesize synthetic metabolic and genetic networks can be tuned for decisions making and in particular to diagnose diseases from biomarkers detections.

This project proposes for the first time a hybrid analogue / digital solution for the multiplexed detection of biomarkers using bacterial and paper-based biosensors. Biosensors can be designed using analog or digital devices. Digital devices in synthetic and natural systems are noise-resistant and useful for decision-making. Analog devices are useful for signal transmission and processing. Here the investigators take advantage of signal transmission and processing via analog transducers and adders, and then decision-making via genetic switches. Such a hybrid analogue / digital approach has not yet been developed for biosensing. Another novelty of the project is to use synthetic metabolic pathways to develop analog devices. The advantage in term of treatment, for example, consists in the fact that the speed of enzymatic reactions in an analog adder far exceeds the speed of gene expression required to create a genetic logic matrix; it becomes even more pronounced when the devices are connected in series. The methodology will be illustrated for the detection of biomarkers of prostate tumors, but it is broad enough to be applicable to other diagnoses. The choice to develop biosensors for prostate disease is of practical relevance since the current screening strategy (based on PSA measurement) can lead to overdiagnosis and cannot differentiate between patients with aggressive tumors and those with an indolent illness.This study propose to mainly develop a bacterial and paper-based biosensor system
Method and apparatus for locating and exchanging clinical information. A method and system are provided for locating and accessing information across a network such as the Internet in a secure manner. With distributed health care records, the system makes it possible to access all parts of a patient's clinical health record even though individual records are dispersed across diverse organizations and providers. One or more servers (102, 103, 503, 604, 605, 606, 805, 808, 809, 1100) contain a correlation system (201, 2209) that accesses databases of universal person objects (208, 507, 2212), and information on what records are available and where they are located. The universal person objects and location information is added to as the server receives metadata (502) from providers (601, 602, 603). Providers who need to find a clinical record can access the server over the network. Once a record has been located, a provider can access a record in a standard format, and in a secure manner.
The invention discloses an anti-cyclophilin A egg yolk antibody, and a preparation method and application thereof. The invention provides a method for preparing a yolk antibody, which comprises the following steps: immunizing a female avian animal with an immunogen, and then collecting yolk antibodies from eggs of the female avian animal; the immunogen has a CypA protein or a CypA fusion protein therein. The invention also protects the yolk antibody prepared by the method. The invention also protects the application of the yolk antibody in preparing anti-inflammatory medicaments. The invention develops an anti-CypA yolk antibody which can be used for inhibiting the inflammatory reaction of organisms. Specifically, the anti-CypA egg yolk antibody has good inflammation inhibition activity against pneumonia, mammitis, endometritis and the like.
The foreign body response (FBR) is an immune-mediated reaction that can occur with most biomaterials and biomedical devices. The FBR initiates a deterioration in the performance of implantable devices, representing a longstanding challenge that consistently hampers their optimal utilization. Over the last decade, significant strides are achieved based on either hydrogel design or surface modifications to mitigate the FBR. This review delves into recent material strategies aimed at mitigating the FBR. Further, the authors look forward to future novel anti-FBR materials from the perspective of clinical translation needs. Such prospective materials hold the potential to attenuate local immune responses, thereby significantly enhancing the overall performance of implantable devices.
BACKGROUND: Placental damage due to viral infections increases risk of adverse perinatal outcomes. Histopathologic examination of placenta can provide information regarding association between infection and outcome. There is paucity of data describing placental pathology with respect to intrauterine fetal death (IUFD) in pregnant mothers affected with COVID-19.
METHODS: 4 fetuses and 10 placentas, including one twin placenta from 9 women with history of IUFD and SARS-CoV-2 infection underwent evaluation. These findings were contrasted with 3 fetuses and 21 gestational age matched placentas from non-infected women with history of IUFD.
RESULTS: Extensive gross placental lesions, mixture of histologic features (maternal/ fetal vascular malperfusion) and isolated cases of massive perivillous fibrin depositon and chronic intervillositis were observed in COVID-IUFD group. There were no distinguishing histologic findings when compared to control. Three fetuses showed signs of intraventricular/intraparenchymal hemorrhage in autopsy.
CONCLUSION: These findings demonstrate that IUFD does not correspond with maternal symptoms and lacks distinctive lesion. However, there was significant placental damage which developed rapidly. These results show that SARS-CoV-2 infection results in rapid placental deterioration and fetal death. This information can be used to educate infected mothers and remind medical professionals, value of monitoring placental function especially following diagnosis of infection.
INTRODUCTION: The comorbidity of optic neuritis with multiple sclerosis has been well recognized. However, the causal association between multiple sclerosis and optic neuritis, as well as other eye disorders, remains incompletely understood. To address these gaps, we investigated the genetically relationship between multiple sclerosis and eye disorders, and explored potential drugs.
METHODS: In order to elucidate the genetic susceptibility and causal links between multiple sclerosis and eye disorders, we performed two-sample Mendelian randomization analyses to examine the causality between multiple sclerosis and eye disorders. Additionally, causal single-nucleotide polymorphisms were annotated and searched for expression quantitative trait loci data. Pathway enrichment analysis was performed to identify the possible mechanisms responsible for the eye disorders coexisting with multiple sclerosis. Potential therapeutic chemicals were also explored using the Cytoscape.
RESULTS: Mendelian randomization analysis revealed that multiple sclerosis increased the incidence of optic neuritis while reducing the likelihood of concurrent of cataract and macular degeneration. Gene Ontology enrichment analysis implicated that lymphocyte proliferation, activation and antigen processing as potential contributors to the pathogenesis of eye disorders coexisting with multiple sclerosis. Furthermore, pharmaceutical agents traditionally employed for allograft rejection exhibited promising therapeutic potential for the eye disorders coexisting with multiple sclerosis.
DISCUSSION: Multiple sclerosis genetically contributes to the development of optic neuritis while mitigating the concurrent occurrence of cataract and macular degeneration. Further research is needed to validate these findings and explore additional mechanisms underlying the comorbidity of multiple sclerosis and eye disorders.
This arm will receive the recruitment letter in an 8.5 x 11 inch envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
After passing Photosan® allergic test, the patients will be injected intravenously with Photosan® (2mg/kg) during 15\~30 minutes, 48 hours prior to a standard craniotomy. Precautions are taken not to expose the patient in the operating room to direct room or operating light and to shield the skin of the flap during operation. Steroids are withdrawn 2-3 days prior to sensitization. After maximal resection, the surface of the tumor bed will be calculated and the generated cavity kept with a balloon containing intralipid (0.1%) or saline and/or artificial spinal fluid in it. A fiber with a spherical diffuser will be centered in the cavity and the surface irradiated with red (625\~635nm) Halogen light. The dose of light irradiation depends on individual condition of the patient, usually with an energy density of 100 J/cm2 at a power density of 500 mW/cm2 to 600 mW/cm2.
One in eight human beings will develop kidney stones during their lifetime. Of these, roughly 20% require surgery. Percutaneous nephrolithotomy (PCNL) is the standard minimally invasive surgical procedure for removal of large kidney stones. In the standard PCNL technique, a drainage tube connecting the kidney to a bag on the outside of the body (nephrostomy tube) is left in place after surgery. Patients are admitted to hospital for one to two days for observation at which time the nephrostomy tube is removed before discharge. The presence of the nephrostomy tube is associated with pain, increased use of opioids, and slower recovery after surgery.

Ambulatory PCNL has been proposed as a way to potentially speed recovery, reduce pain, decrease time in hospital, and decrease cost. Initial studies of ambulatory tubeless PCNL have shown favourable results. However, these studies were performed in a small subset of healthy patients with favourable stones that do not represent the majority of patients who undergo PCNL. In this technique, patients are discharged home the same day as surgery usually with a small drainage tube on the inside of the body called a stent that is removed 1-2 weeks later and no nephrostomy tube (tubeless). The stent itself can be painful and may require a second procedure for removal. There is increasing evidence for the safety of totally tubeless PCNL (in which no nephrostomy tube or ureteric stent is placed) or placement of a stent on a string for a short period of time. Given that current recommendations for stone management in the times of COVID-19 include minimizing use of stents, the investigators believe it is an optimal time to evaluate safety and efficacy of using a minimal stenting technique (either no stent at all or stent on string) in ambulatory PCNL patients.

The goal of the study is to determine if ambulatory tubeless PCNL is safe and effective compared to inpatient PCNL with a nephrostomy tube in a more representative patient population including obese patients, patients with moderate medical comorbidities, and patients with large kidney stones. A secondary aim is to determine if a minimal stent technique (stent on a string for 5 days or less or no stent) is safe and effective as an exit strategy in ambulatory PCNL patients. The study hypothesis is that ambulatory tubeless PCNL will have similar complication and stone free rates as inpatient PCNL with benefits over inpatient PCNL including improved patient quality of life, decreased use of opioid pain medications, shortened hospital admission, faster return to work, and lower cost.
Premenstrual syndrome is the clinical condition in which reproductive age females suffer from emotional and physical symptoms not related to any disease, starting usually five days before the menstrual cycle for three consecutive cycles. As menstrual cycle starts in females these symptoms vanish on 4th day of menstruation. Around 10% to 53% of female adults suffer from this condition. This condition limits activities of daily life and adversely effects the quality of life therefore, the administration of proper medical intervention is very important. Aerobic exercises and progressive muscle relaxation exercises have been effective in the treatment of premenstrual syndrome previously in a few studies. However, these two interventions have never been compared to test their effects on pain, and functional performance.
OBJECTIVE: This study aimed to investigate the effects of combining remimazolam with estazolam on hemodynamics and pain levels after laparoscopic gastrointestinal surgery.
METHODS: A total of 184 patients who underwent laparoscopic gastrointestinal surgery were enrolled in this double-blind randomized controlled trial. The patients were divided into four groups: Study Group 1(Remimazolam), Study Group 2(Estazolam), Study Group 3(Remimazolam + Estazolam), and Control Group. Anesthesia induction included intravenous injection of remimazolam and estazolam in the study groups, while the control group received normal saline. Hemodynamic parameters, stress responses, anxiety levels, and pain intensity were assessed at various time points.
RESULTS: The results showed that the combination of remimazolam and estazolam significantly improved hemodynamic parameters compared to the control group. Study Group 3 exhibited the lowest anxiety levels and stress responses among all groups. Furthermore, Study Group 3 had the lowest pain intensity scores at different postoperative time points.
CONCLUSION: The combination of remimazolam and estazolam effectively stabilized hemodynamics, reduced anxiety levels, and alleviated pain intensity after laparoscopic gastrointestinal surgery. These findings suggest that this combination therapy has the potential to improve surgical outcomes and patient comfort.
In June 2021, Chinese Food and Drug Administration approved the launch of the self-developed new drug Tenofovir Amibufenamide(TMF). TMF is the phosphoramidite precursor of Tenofovir, belonging to the nucleoside reverse transcriptase and owning higher cell membrane penetration rate, which make it easier to enter hepatocytes and achieve liver-targeted therapy. Meanwhile, TMF can effectively improve drug stability in plasma and reduce systemic tenofovir(TFV) exposure, and make long-term treatment safer.

Previous studies have shown that tenofovir disoproxil (TDF), the first generation of TFV, had the effect of lowering blood lipids. While patients who switched to tenofovir alafenamide (TAF), the second generation of TFV, had elevated blood lipids. TMF is a new second generation of TFV and its effect on blood lipids is unclear. Our study aims to figure out the effect of TMF on serum lipid level in the process of antiviral therapy for chronic hepatitis B patients.
PROBLEM TO BE SOLVED: To obtain the subject medicinal agent containing an isoquinoline having a specific structure as active ingredient, inhibiting NF-kB, and useful for preventing/treating such diseases as to be caused by inflammatory cytokine's abnormal production or the increased manifestation of inflammatory cell adhesion molecules. SOLUTION: This medicinal agent contains, as effective component, a substituted isoquinoline derivative (an acid-added salt thereof) of formula I [R1 is H, Cl, etc.; when R1 is H, R2 is a group from a compound of formula II (A is a 2-4C alkyl either nonsubstituted or substituted by a 1-4C alkyl for an H atom bound to a carbon atom; R3 and R4 are each H, etc.; R5 is H, etc.)], e.g. 1-(-isoquinolinesulfonyl)-4-aminopiperidine. The compound of formula I is obtained, for example, by reaction between 5-isoquinolinesulfonic acid chloride and homopiperazine. This medicinal agent is used as a preventive/therapeutic agent for e.g. chronic arthrorheumatism, an immunosuppressive agent to be used in organ transplantation, an antiviral agent, etc.
The application of conventional endoscopy in remote and outdoor areas lacking facilities remains challenges. Thus, the investigators developed a novel portable upper gastrointestinal endoscopy system that has the same functions as conventional endoscopy. A total of 24 participants from a medical unit on a remote island in China underwent endoscopy with the portable system between March and June 2021. The portable system packed into a suitcase is 68 × 42 × 32 cm in size, weighing less than 35 kg, and comprises a disposable sheathed system. The examination time and any malfunctions in the portable endoscopy system during the examination were recorded. After the examination was finished, the disposable sheathed system was removed, and a pressure leak test was performed to check the seal of the system. The patients were followed up within three days to confirm any adverse events such as nausea, vomiting, throat discomfort, bleeding, etc.
The present study aimed to examine the efficacy of an intervention, based on the Health Belief Model (HBM) and social support, in promoting strength training (ST) among older adults. A two-arm clustered randomized controlled trial (RCT) was conducted among 235 older adults from eight elderly centers in Hong Kong. The intervention group engaged in a 6-month intervention comprising ST sessions, exercise consultations, social gatherings, and a buddy program, while the control group participated in social gatherings. Assessments were conducted at baseline (Month 0), post-intervention (Month 6), and 3-month follow-up (Month 9), with primary outcome being the prevalence of meeting the American College of Sports Medicine (ACSM) recommendations of ST. Results showed that the intervention group reported significantly higher prevalence of meeting ACSM recommendations for ST at both post-intervention and follow-up. Linear mixed models showed significant interaction effect between condition and time on perceived susceptibility of sarcopenia and muscle strength and significant condition effect on self-efficacy for ST, perceived severity of sarcopenia, perceived barriers of ST, and intention to perform ST. Findings suggest that the intervention, guided by HBM and social support, improves older adults' ST participation, muscle strength, perceptions on sarcopenia, and self-efficacy for ST, which offers great potential for broader application in other settings.